
Corporate Governance Statement

Mesoblast Limited (the **Company** or **Mesoblast**) and its Board of Directors (the **Board**) are committed to maintaining an effective corporate governance framework to ensure that the Company is managed effectively and in an honest and ethical way.

A description of the Company and its controlled entities' (together, the **Group**) corporate governance practices is set out below. All of these practices, unless otherwise stated, were in effect for the financial year ended 30 June 2026 and comply with the ASX Corporate Governance Council's (**Council**) Corporate Governance Principles and Recommendations, fourth edition (the **ASXCGPR**).

The information in this Statement is current as at 1 October 2026 and has been approved by the Board.

This Statement includes cross-references to the Company's charters, policies and codes, relevant copies or summaries of which are available in the Corporate Governance section of the Company's website, www.mesoblast.com. Further, this Statement should be read in conjunction with the Directors' Report, the Remuneration Report and the Financial Report for the financial year ended 30 June 2026, and the Environmental, Social and Governance (**ESG**) Statement, as these reports also contain information required or recommended to be included by the ASXCGPR. The Directors' Report can be found at Part 1 of the Form 20-F contained within our 2026 Annual Report (principally Item 6.A), the Remuneration Report can be found at Item 6.B of the Form 20-F contained within the 2026 Annual Report, the Financial Report can be found at Item 18 of the Form 20-F contained within the 2026 Annual Report, and the ESG Statement can be found at Item 4 of the Form 20-F contained within the 2026 Annual Report.

PRINCIPLE 1. LAY SOLID FOUNDATIONS FOR MANAGEMENT AND OVERSIGHT

ROLE OF THE BOARD

The Board of Directors is primarily responsible for setting the strategic direction and corporate governance of the Group, and for overseeing the management and operations of the Group. In particular, the principal roles and responsibilities of the Board are to:

- facilitate accountability of the Group to the Company's shareholders;
- ensure timely reporting to shareholders;

- provide strategic guidance to management, including contributing to the development and review of the corporate strategy;
- oversee management of the Group and ensure there are effective management processes in place;
- appoint, remove (if necessary) and monitor the performance of the Chief Executive;
- review the performance of the Board, individual Directors and the committees of the Board;
- monitor:
 - organizational performance and the achievement of the Group's strategic goals and objectives;
 - financial performance including approval of the annual and half-year financial reports, and liaison with the Company's auditors;
 - progress of major capital expenditure and other significant corporate projects including any acquisitions or divestments;
 - compliance with the Group's corporate governance policies and procedures; and
 - progress in relation to the Group's diversity objectives and compliance with its diversity policy;
- review and approve business plans, the annual budget and financial plans (including available resources and major capital raising or expenditure initiatives);
- approve major corporate initiatives;
- enhance and protect the reputation of the Group including through the Group's statement of values and code of conduct;
- oversee the operation of the Group's system for compliance and risk management, including in relation to cybersecurity; and
- ensure appropriate resources are available to senior management.

The Board operates in accordance with the broad principles set out in its charter, which provides a framework for the Board's effective operation. The charter specifically addresses the following:

- role, authority and responsibilities of the Board;
- Board committees;
- Board composition and election of the Chair;
- Directors' rights and duties;

- responsibilities of and delegations to management;
- performance of the Board; and
- role of a Company Secretary.

A summary of the charter is available at the Corporate Governance section of the Company's website, www.mesoblast.com.

BOARD COMMITTEES

The Board has delegated specific authority to three committees. These committees are:

- the Nomination and Remuneration Committee;
- the Audit and Risk Committee; and
- the Clinical Committee.

The role and responsibilities of these committees are set out in each Board committee's charter. Further details on the Nomination and Remuneration Committee and Audit and Risk Committee are at Principle 2 and Principle 4 of this Statement, respectively.

The Clinical Committee was established by the Board in January 2026 and is primarily responsible for making recommendations to the Board on:

- the strategic direction of our clinical development programs and product candidates;
- the alignment of our clinical development programs and research activities with our strategic objectives;
- the prioritization of, and progress against, our key clinical development programs;
- our regulatory strategy for product approvals and our interactions with regulatory agencies; and
- significant emerging scientific, medical and regulatory developments relevant to our business.

The Clinical Committee's objective is to leverage the clinical, medical and scientific expertise of its members to provide strategic input that supports the Board's oversight of our clinical development activities. The committee's role is advisory.

The following Directors are the members of the Clinical Committee as at 30 June 2026:

Name	Position
Gregory George	Chair
William Burns	Member
Philip Krause	Member
Silviu Itescu	Member
Eric Rose	Member

The Clinical Committee charter is available at the Corporate Governance section of the Company's website, www.mesoblast.com.

ROLE OF MANAGEMENT

Day-to-day management of the Group's operations and the implementation of the corporate strategy and policy initiatives are delegated by the Board to the Chief Executive and the executive team.

Specific limits of authority delegated to the Chief Executive and the senior executive team are outlined in a formal delegation of authority policy, which has been approved by the Board.

DIRECTOR SELECTION AND APPOINTMENT

The Company conducts appropriate checks before it appoints a person or puts forward to shareholders a new candidate for election as a Director. These include checks as to the person's character, experience, education, criminal record, bankruptcy history, probity and any other relevant matters.

The Company also provides shareholders with all material information in its possession relevant to a decision on whether or not to elect or re-elect a Director in the notice of meeting provided to shareholders. This includes information relevant for shareholders to be able to assess each Director's skills and competencies, industry experience, time commitments, current directorships, and other relevant information in their consideration of that election, including any other interest, position or relationship that might influence their capacity to bring an independent judgement to bear on issues before the Board and to act in the best interests of the Company as a whole rather than in the interests of an individual shareholder or other party.

WRITTEN AGREEMENTS WITH DIRECTORS AND SENIOR EXECUTIVES

The Company has a written agreement with each Director and senior executive setting out the terms of their appointment.

The roles and responsibilities of each non-executive Director are set out in their letter of appointment, which the Director receives and commits to on their appointment. The letter of appointment specifies the time commitment, expectations in relation to committee work or any other special duties attaching to the Director's position, reporting lines, remuneration arrangements, disclosure obligations in relation to personal interests, confidentiality obligations, insurance and indemnity entitlements and details of the Company's key governance policies. The key governance policies are available at the Corporate Governance section of the Company's website, www.mesoblast.com.

Each executive Director and senior executive has entered into a service contract that sets out the material terms of employment, including a description of position and duties, reporting lines, remuneration arrangements and termination rights and entitlements. Further details on arrangements which apply to each executive Director and those senior executives who are designated key management personnel can be found in Item 6 of the Form 20-F contained within our Annual Report.

COMPANY SECRETARIES

The Company Secretaries are accountable directly to the Board, through the Chair, on all matters to do with the proper functioning of the Board. The Company Secretaries assist the Board in its effectiveness by monitoring that Board policies and procedures are followed, and by coordinating the timely completion and dispatch of the Board agenda and supporting papers. The Directors have direct access to the Company Secretaries, who regularly communicate with them through email, by telephone and at in-person meetings.

DIVERSITY

The Group values diversity and recognizes the benefits that diversity can bring to the organization's ability to achieve its goals. Diversity can lead to a competitive advantage through broadening the talent pool for recruitment of high-quality employees, by encouraging innovation and improving a corporation's professionalism and reputation. Accordingly, the Group is committed to promoting diversity within the Group and has adopted a formal policy outlining the Group's diversity objectives.

A copy of the diversity policy is available at the Corporate Governance section of the Company's website, www.mesoblast.com.

With respect to gender diversity, the Group has set the following objectives:

- 1) aim to increase the number of women on the Board of Directors as vacancies arise and circumstances permit;
- 2) aim to increase the number of women who hold senior executive positions as vacancies arise and circumstances permit; and
- 3) ensure the opportunity exists for equal gender participation in all levels of professional development programs.

The Group is committed to developing a workplace that promotes diversity by acting with fairness, objectivity and without prejudice. The Group's policy is to recruit and manage on the basis of competence and performance, regardless of ethnicity, gender, age, sexual orientation, religion, socio-economic status and physical ability. Accordingly, the Group has not established measurable objectives or numerical targets for achieving gender diversity. The Board considers that given the size of the Group's workforce and its recruitment on merit policy, the setting of specific numerical targets would not be appropriate at this time. The Board will continue to monitor the need for measurable objectives as the Group grows.

The following table reports the Group's progress towards achieving its gender diversity objectives for points one and two above. In regard to point three, the Group ensured that an equal opportunity existed for gender participation in all levels of professional development programs during the financial year. For completeness, as at 30 June 2026, the Group globally had 108 employees, of which 62 (57%) were female.

Category	Number of women at 30 June 2026	Number of women at 30 June 2025	Increase/ (Decrease)
Board of Directors	2	2	–
Senior executive positions*	3	3	–

* A senior executive position is one held by an executive who reports directly to the Chief Executive. Approximately 30% of senior executive positions were held by women as at 30 June 2026.

The Board acknowledges that diversity and inclusion contribute to enhanced decision-making and governance outcomes, and is committed to ensuring that future Board appointments are guided by these principles. There are currently two female Directors on the Board: Ms Lyn Cobley AM, who was appointed in 2025 and is the current Chair of the Audit and Risk Committee, and Ms Jane Bell AM, who is the current Co-Chair of the Nomination and Remuneration Committee and former Chair of the Board.

The Board has delegated the responsibility for reviewing and reporting on diversity, specifically gender diversity, to the Nomination and Remuneration Committee.

BOARD PERFORMANCE EVALUATION

The performance of the Board, its committees, individual Directors and senior management is reviewed periodically. A copy of the Group's performance evaluation process is available at the Corporate Governance section of the Company's website, www.mesoblast.com. This review encompasses feedback on the Chair and individual non-executive Directors as well as consideration of Board succession planning, diversity, and the breadth and sufficiency of skills represented on the Board. The results of the review are discussed by the Board, for the purpose of confirming that the Board continues to function in an appropriate manner.

The Board also regularly carries out informal performance monitoring discussions during director-only sessions at Board meetings, and such discussions occurred in the financial year ended 30 June 2026. In addition, Directors are encouraged to raise any issues or concerns regarding the performance of the Board, Board committees or individual Directors with the Chair, or if the concern relates to the Chair, with the Chair of the Audit and Risk Committee.

SENIOR EXECUTIVE PERFORMANCE EVALUATION

The process for assessing performance of the Chief Executive and the senior executive team is described in the Remuneration Report. A performance evaluation for senior executives, which accords with the process described in the Remuneration Report, was undertaken with respect to the financial year ended 30 June 2026.

PRINCIPLE 2.

STRUCTURE THE BOARD TO BE EFFECTIVE AND ADD VALUE

NOMINATION AND REMUNERATION COMMITTEE

The Board has a Nomination and Remuneration Committee to assist it in the discharge of its responsibilities, and in particular to ensure that appointments to the Board are subject to formal, rigorous and transparent procedures in order to create an environment where the Board can carry out effective and responsible decision-making and oversight. The main responsibilities of the Nomination and Remuneration Committee are to:

- conduct reviews of the membership of the Board having regard to present and future needs of the Company, and to make recommendations on Board composition, appointments and reappointments;
- conduct reviews of and determine the independence of each Director;
- propose candidates for Board vacancies;
- oversee annual executive performance evaluations, including recommendations for long- and short-term incentive grants as well as pay reviews;
- oversee Board succession, including the succession of the Chair, and review whether succession plans are in place to maintain an appropriately balanced mix of skills, experience and diversity on the Board;
- manage the processes in relation to meeting Board diversity objectives;
- oversee senior management succession plans; and
- assess the effectiveness of the Board induction process.

The Nomination and Remuneration Committee operates in accordance with its charter which sets out its roles and responsibilities, composition, structure and membership requirements. A summary of the Nomination and Remuneration Committee charter is available at the Corporate Governance section of the Company's website, www.mesoblast.com.

The following independent Directors are the members of the Nomination and Remuneration Committee as at 30 June 2026:

Name	Position
William Burns	Independent Co-Chair
Jane Bell AM	Independent Co-Chair
Philip Facchina	Independent member
Lyn Copley AM	Independent member

The details of the meetings attended by each member of the Nomination and Remuneration Committee during the 2026 financial year are set out in Item 6.B of the Form 20-F contained within our Annual Report.

BOARD SKILLS MATRIX

The Company has developed a skills matrix setting out the mix of skills and diversity that the Board currently has or is looking to achieve in its membership. The skills matrix helps to identify any gaps in the collective skills of the Board that can then be addressed through professional development initiatives for Directors and in Board succession planning. The Nomination and Remuneration Committee regularly reviews the skills matrix to make sure it covers the skills needed to address existing and emerging business and governance issues relevant to the Company.

The skills and experience that the Board has, and continues to add to its membership, are in the areas of, but not limited to:

- Industry experience: pharmaceutical/biotechnology product development – substantial experience in the drug investigation, testing and development process;
- Industry experience: pharmaceutical/biotechnology commercialization and regulatory – substantial experience in the drug commercialization process including clinical trials and path to regulatory and pricing approval;
- Industry experience: pharmaceutical/biotechnology manufacturing and supply – substantial experience in the global manufacturing, quality control and supply of approved pharmaceutical products;
- Executive management and leadership: substantial experience in managing and leading organizations at senior executive and board levels;
- Global business/commercial experience: substantial experience in senior executive roles for businesses operating across multiple global locations;
- Strategy: substantial experience in the development and implementation of strategic direction and plans to deliver investor returns over time;
- Corporate financing, mergers and acquisitions: substantial experience in capital raisings, mergers and acquisitions of companies and complementary technologies;
- Financial and risk management: expertise and experience in audit, financial accounting and reporting, internal controls, financial disclosure and industry taxation;
- Human resources: substantial experience in stakeholder management, oversight of remuneration, incentives, equity programs, benefits, employment contracts and workplace health and safety;
- Corporate governance: substantial experience in public entity disclosure, management oversight and inquiry, listing rules and compliance; and
- Medical/healthcare leadership: substantial leadership experience in healthcare organizations and/or integrated healthcare delivery.

Each of these skills is well represented on the Board.

INDEPENDENT DIRECTORS

As at 30 June 2026, the Board included the following independent Directors:

- Mr Philip Facchina;
- Mr William Burns;
- Ms Jane Bell AM; and
- Ms Lyn Cobley AM.

As at 30 June 2026, 50% of the Board were independent Directors, which does not constitute the majority recommended by ASXCGPR Recommendation 2.4. The Board, as part of succession planning, is looking to increase the percentage of independent Directors on the Board. A Director is considered independent if he or she is a non-executive Director and is free of any interest, position, association or relationship that might influence, or reasonably be perceived to influence, in a material respect his or her capacity to bring an independent judgement to bear on issues before the Board. The Board considers the factors set out in the ASXCGPR and outlined below when assessing the independence of each non-executive Director, being whether the Director:

- is, or has been, employed in an executive capacity by the Group and there has not been a period of at least three years between ceasing such employment and serving on the Board;
- receives performance-based remuneration (including options or performance rights) from, or participates in, an employee incentive scheme of, the Group;
- is, or has within the last three years been, a partner, director, senior employee or consultant of a provider of material professional services to the Group;
- is, or has been within the last three years, in a material business relationship (e.g. as a supplier, professional advisor, consultant or customer) with the Group, or is an officer of, or otherwise associated with, someone in such a relationship;
- is, represents, or is or has been within the last three years an officer or employee of, or professional advisor to, a substantial security holder of the Group;
- has a material contractual relationship with the Group other than as a Director;
- has close personal ties, which may be based on family, friendship, or other social or business connections, with any person who falls within any of the categories described above; or
- has been a Director of the Company for such a period that their independence from management and substantial holders may have been compromised.

The Board at least annually assesses the independence of its non-executive Directors. To enable this assessment of independence, the Company maintains a conflicts of interest register, and the Directors must provide all information that may be relevant to the assessment at the earliest opportunity in accordance with the Directors Conflict of Interest Policy.

As part of its annual assessment of independence for the 2026 financial year, the Board gave specific consideration to:

- the fact that our non-executive Directors have received options under our employee incentive scheme;
- the independence of Mr Facchina, who is Chief Strategy Officer of SurgCenter Development. SurgCenter Development is not a security holder in Mesoblast. However, some of its principals were lead investors in Mesoblast's recent capital raisings and are substantial shareholders in the Company;
- the independence of Dr Krause, who performed a strategic advisory role for the Company under a consulting agreement with his company until 31 March 2026, in addition to his role as non-executive Director; and
- the independence of Dr George, who is a substantial shareholder in the Company.

With respect to the options previously granted to non-executive Directors, it is the Board's view that these options will not interfere with the Directors' capacity to bring an independent judgement to bear on issues before the Board and to act in the best interests of the Group as a whole. It is noted that the options granted to independent non-executive Directors, unlike other options granted to employees, are not subject to any performance or service conditions or hurdles.

With respect to Mr Facchina, the Board considers that Mr Facchina brings independent judgement, experience and expertise to the Board on behalf of all shareholders and that he does not represent the interests of any particular shareholder or group of shareholders.

With respect to Dr Krause, the Nasdaq rules have a financial threshold for payments to directors (other than director fees and committee fees) above which a director is no longer considered independent. Because that threshold has been exceeded in relation to Dr Krause's remuneration under his previous strategic advisory role for the Company, he is not considered an independent Director.

As a more than 10% shareholder, Dr George is an "affiliate" under the United States Securities and Exchange Commission (**SEC**) rules and, as a result, is not considered an independent Director.

Dr Itescu and Dr Rose are executive Directors and members of the Company's management team. As such, they are not considered independent Directors.

CHAIR

The Chair is responsible for leading the Board and for the efficient organization and conduct of the Board.

The role of the Chair more specifically is to ensure Directors are properly briefed on all matters relevant to their role and responsibilities, to facilitate Board discussions and to manage the Board's relationship with the Chief Executive and executive team. In accepting the position, the Chair has acknowledged

that it will require a significant time commitment and has confirmed that other positions held will not hinder his effective performance in the role of Chair. The Chair, Mr Philip Facchina, is considered an independent Director.

TERM OF OFFICE

The Company's Constitution specifies that no Director, except the Chief Executive, may hold office for a period in excess of three years, or beyond the third Annual General Meeting following the Director's election, whichever is the longer, without submitting himself or herself for re-election.

The term of office held by each Director as at 30 June 2026 is as follows:

Director	Term as Director	Position held at 30 June 2026
Philip Facchina	5 years and 3 months	Independent Chair
William Burns	12 years and 3 months	Independent Vice-Chair
Silviu Itescu	22 years	Executive Director
Philip Krause	4 years and 3 months	Non-Executive Director (not independent)
Eric Rose	13 years and 2 months	Executive Director
Jane Bell AM	3 years and 10 months	Independent Director
Gregory George	1 year and 4 months	Non-Executive Director (not independent)
Lyn Cobley AM	1 year and 2 months	Independent Director

BOARD INDUCTION AND PROFESSIONAL DEVELOPMENT

All new Directors participate in an informal induction program which covers the operation of the Board and its committees, and an overview of the Group's core programs, key strategy, financial and relevant operational documents. The induction also includes meetings with existing Directors and senior executives to ensure all relevant and material information is explained thoroughly. The induction provided to new Directors enables them to actively participate in Board decision-making as soon as possible.

The Board encourages Directors to identify opportunities for, and to participate in, continuing education. The Board actively assesses relevant conferences and presentations that are appropriate for Directors to attend, particularly in the field of regenerative medicine, to heighten their understanding of the Group's core technologies and industry.

In addition, presentations from management and external advisors are included in the agenda for Board meetings throughout the year to assist with keeping the Directors updated and informed on key developments in laws and the regulatory environment.

PRINCIPLE 3.

INSTIL A CULTURE OF ACTING LAWFULLY, ETHICALLY AND RESPONSIBLY

CODE OF CONDUCT AND VALUES

As part of its commitment to recognizing the legitimate interests of stakeholders, the Group has a code of conduct (**Code**), statement of values and a suite of policies and procedures to guide all Directors and employees in respect of ethical and compliant behaviour expected by the Group. In summary, the Code requires that at all times all Company personnel act with the utmost integrity, objectivity and in compliance with the law and Company policies. More specifically, the Code covers the following:

- conflicts of interest;
- confidentiality;
- fair dealing;
- protection of assets;
- compliance with laws and regulations;
- reporting violations of the Code;
- securities trading; and
- commitments to stakeholders.

A copy of the Code and statement of values can be found at the Corporate Governance section of the Company's website, www.mesoblast.com.

OTHER POLICIES

Among its suite of policies and procedures, the Company has an Anti-Bribery and Anti-Corruption Policy and provides associated training in respect of the policy as well as the Code. In addition, the Company has a Disclosure of Complaints and Concerns Policy (which serves as the Company's whistleblower policy for the purposes of ASXCGPR Recommendation 3.3) which addresses, among other things, alleged breaches under the Company's Code, Anti-Bribery and Anti-Corruption Policy, or other Company policies. These policies can be found at the Corporate Governance section of the Company's website, www.mesoblast.com. The Company has a process in place to inform the Board or a committee of the Board of any material breaches of the Anti-Bribery and Anti-Corruption Policy, Code and material incidents reported under the Disclosure of Complaints and Concerns Policy.

PRINCIPLE 4.

SAFEGUARD THE INTEGRITY OF CORPORATE REPORTS

AUDIT AND RISK COMMITTEE

The Board has an Audit and Risk Committee to which it has delegated the responsibility for ensuring that an effective internal control framework exists within the Group. The main responsibilities of the Audit and Risk Committee with respect to financial reporting are to:

- review and assess the annual financial report, the half-year financial report, the Company's quarterly accounts and all other financial information published by the Company or released to the market;

- recommend to the Board the appointment, removal and remuneration of the external auditors, and review the terms of their engagement, the scope and quality of the audit and assess performance;
- consider the independence and competence of the external auditor on an ongoing basis;
- review and approve the level of non-audit services provided by the external auditors and ensure it does not adversely impact on auditor independence;
- review and monitor related party transactions;
- oversee the effective operation of the risk management framework;
- oversee and review the Company's compliance with the Disclosure of Complaints and Concerns Policy by Mesoblast personnel;
- assist the Board in reviewing the effectiveness of the organization's internal control environment covering:
 - effectiveness and efficiency of operations and business processes;
 - safeguarding of assets;
 - reliability of financial reporting and maintaining proper accounting records; and
 - compliance with applicable laws and regulations; and
- report to the Board on matters relevant to the committee's role and responsibilities.

In fulfilling its responsibilities, the Audit and Risk Committee:

- receives regular reports from management and the external auditors;
- meets with the external auditors at least twice a year, or more frequently if necessary;
- reviews the processes which the Chief Executive and Chief Financial Officer have in place to support their certifications to the Board;
- reviews any significant disagreements between the auditors and management, irrespective of whether they have been resolved; and
- provides the external auditors with a clear line of direct communication at any time to either the Chair of the Audit and Risk Committee or the Chair of the Board. The Audit and Risk Committee has authority, within the scope of its responsibilities, to seek any information it requires from any employee or external party.

The Audit and Risk Committee operates under a formal charter approved by the Board which sets out the committee's role and responsibilities, composition, structure and membership requirements and the procedures for inviting non-committee members to attend meetings. A full copy of the Audit and Risk Committee charter can be found at the Corporate Governance section of the Company's website, www.mesoblast.com.

The following independent Directors are the members of the Audit and Risk Committee as at 30 June 2026:

Name	Position
Lyn Cobley AM	Independent Chair
Jane Bell AM	Independent member
Philip Facchina	Independent member

All members of the Audit and Risk Committee are financially literate and have a finance background. The relevant qualifications and experience of each member of the Audit and Risk Committee are set out in the Directors' Report in our Annual Report.

Additionally, Mr Facchina and Ms Bell have valuable and relevant industry experience having served in the healthcare industry in senior positions for a number of years. The details of the meetings attended by each member of the Audit and Risk Committee during the 2026 financial year are set out in Item 6.B of the Form 20-F contained within our Annual Report.

CHIEF EXECUTIVE AND CHIEF FINANCIAL OFFICER DECLARATION

The integrity of the Company's financial reporting depends upon the existence of a sound system of risk oversight and management and internal control.

Management accountability for this is enhanced by the assurances it is required to give to the Board.

The Chief Executive and the Chief Financial Officer provided assurance to the Board prior to release of the Company's 2026 financial year financial statements that, in their opinion:

- the financial records of the Company for the financial year have been properly maintained in accordance with the *Corporations Act 2001* (Cth); and
- the financial statements and notes for the relevant financial period comply with the accounting standards and give a true and fair view of the financial position and performance of the Group.

The opinions of the Chief Executive and the Chief Financial Officer were formed on the basis of a sound system of risk management and internal control which is operating effectively in all material respects in relation to financial reporting risks, and are supported by similar certifications from other members of the management team.

INTEGRITY OF PERIODIC CORPORATE REPORTS

The Company has a policy and procedures in place to ensure that periodic corporate reports which are not subject to audit or review by an external auditor comply with relevant disclosure obligations under applicable laws. A copy of the Company's market disclosure and shareholder communications policy can be found at the Corporate Governance section of the Company's website, www.mesoblast.com.

PRINCIPLE 5.

MAKE TIMELY AND BALANCED DISCLOSURE

CONTINUOUS DISCLOSURE

The Company has a policy and procedures in place to ensure that it identifies and discloses any information concerning the Group that a reasonable person would expect to have a material effect on the price of the Company's securities (price sensitive information) in accordance with the continuous disclosure requirements under ASX Listing Rule 3.1. The Company's policy in relation to market disclosure and shareholder communications can be found at the Corporate Governance section of the Company's website, www.mesoblast.com.

The Company has established an internal review committee which reviews all market announcements (other than routine administrative announcements) to ensure they are factual, comply with legal obligations, do not omit material information, provide a balanced view, and are presented in a clear and concise way.

The Board receives copies of all material market announcements either prior to or promptly after they have been made.

All price sensitive information disclosed to the ASX is posted on the Mesoblast website as soon as possible after it is disclosed to the ASX.

Where the Company holds a substantive investor or analyst presentation, including for its quarterly financial results, or one which contains material new information, the material used in the presentation is released to the ASX ahead of or concurrently with the presentation and posted on the Mesoblast website.

PRINCIPLE 6.

RESPECT THE RIGHTS OF SECURITY HOLDERS

COMPANY WEBSITE

The Company provides information about itself and its governance on its website at www.mesoblast.com.

INVESTOR RELATIONS

Mesoblast's investor relations program involves scheduled and ad hoc interactions with institutional investors, private investors and sell-side and buy-side analysts to facilitate understanding of the Group's business, corporate strategy, governance, financial and operational performance and prospects.

Further, shareholders can contact the Company at any time through the Company's Investor Relations team. The contact details are available on www.mesoblast.com. The Board receives regular reports from the Chief Executive, Chief Financial Officer and Investor Relations personnel regarding feedback from shareholders and analysts. This ensures Directors are aware of concerns being raised, giving them a good understanding of current market and shareholder views.

Where possible, the Company arranges for advance notification of significant group briefings (including, but not limited to, financial results announcements) and makes them widely accessible. Webcasts of analysts' calls are generally available on the Company's website at www.mesoblast.com.

SHAREHOLDER MEETINGS

The Board encourages full participation by shareholders at the Annual General Meeting to ensure a high level of Director accountability to shareholders and to enhance shareholders' identification with the Group's strategy and goals. The shareholders are requested to vote on matters such as the adoption of the Remuneration Report, the granting of securities to Directors and changes to the Constitution. Importantly, Mesoblast facilitates and encourages shareholder participation at the Annual General Meeting by providing a question forum at the meeting to address individual shareholder queries. The Company determines all resolutions at its Annual General Meeting by poll. The Board is committed to monitoring ongoing developments that may enhance communication with shareholders, including technology developments.

COMMUNICATIONS

Mesoblast gives shareholders the option to receive communications from, and send communications to, Mesoblast and its share registry electronically.

PRINCIPLE 7.

RECOGNIZE AND MANAGE RISK

AUDIT AND RISK COMMITTEE

The Board is responsible for satisfying itself annually, or more frequently as required, that management has developed and implemented a sound system of risk management and internal control. Detailed work on this task is delegated to the Audit and Risk Committee and reviewed by the full Board. The Audit and Risk Committee is responsible for ensuring there are adequate policies in relation to risk management, compliance and internal control systems. The committee monitors the Group's risk management by overseeing management's actions in the evaluation, management, monitoring and reporting of material operational, financial, compliance and strategic risks. In providing this oversight of the Company's risk management systems and practices, the committee:

- reviews the framework and methodology for risk identification, the degree of risk the Company is willing to accept, the management of risk and the processes for auditing and evaluating the Group's risk management system;
- reviews Group-wide objectives in the context of the abovementioned categories of corporate risk;
- reviews and, where necessary, approves guidelines and policies governing the identification, assessment and management of the Group's exposure to risk;
- reviews and approves the delegations of financial authorities and addresses any need to update these authorities on an annual basis; and
- reviews compliance with agreed policies.

The committee recommends any actions it deems appropriate to the Board for its consideration. Details of the committee's charter, composition, structure, membership and attendance at meetings by members can be found under Principle 4 of this Statement.

RISK MANAGEMENT FRAMEWORK

The Board is responsible for satisfying itself annually, or more frequently as required, that management has developed and implemented an effective system of risk management and internal control. Management is responsible for ensuring there are adequate policies in relation to risk management, compliance and internal control systems. The Audit and Risk Committee monitors the Group's risk management by overseeing management's actions in the evaluation, management, monitoring and reporting of material operational, financial, compliance, strategic, cybersecurity and certain ESG risks.

Mesoblast's risk management group is part of executive management. This group is responsible for designing, implementing, monitoring and reporting on the Group's management of material business risks and the effectiveness of the Group's risk management and internal control system. ESG risks have been incorporated into and are considered as part of Mesoblast's risk management system. The risk management group reviews the Group's risks across its business and operations, and the Group's material business risks and risk management framework are reviewed at least annually by the Audit and Risk Committee.

The Group has a standardized tool to assess the Group's portfolio and corporate risk. Since the commercial launch of Ryoncil® in March 2025, we have updated the standardized tool to incorporate commercial product risks. Further detail on risks can be found in the 'Risk Factors' section (Item 3.D) of the Form 20-F contained within our Annual Report.

INTERNAL AUDIT FUNCTION

In light of the size and nature of the Company's operations and activities, the Company has not established a formal separate internal audit function. The Company does have, however, a Quality Management Department with appropriate controls in place for monitoring and compliance of clinical and non-clinical studies as well as manufacturing and distribution operations. The Company also has a compliance function which establishes the controls for and monitors compliance with the Company's Code, policies and applicable healthcare-related laws and regulations.

The processes the Company employs to evaluate and continually improve the effectiveness of its governance, risk management and internal control processes include the Audit and Risk Committee's annual review of the risk management framework, management reporting to the Audit and Risk Committee on key risks, Chief Executive and Chief Financial Officer declarations in accordance with ASXCGPR Recommendation 4.2, and engagement of external advisors as required.

As part of our Nasdaq listing, we are required to comply with rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002.

To meet these requirements, the Company's management is responsible for establishing and maintaining adequate internal control over financial reporting. External auditors and the Company's management conducted an assessment of the effectiveness of its internal control over financial reporting as of 30 June 2026 and have concluded that its internal control over financial reporting was effective as of that date.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) RISKS

The Group monitors its exposure to risks, including ESG risks. The ESG Statement, which can be found at Item 4 of the Form 20-F contained within the 2026 Annual Report, sets out at a high level the Group's approach to ESG matters.

ESG issues previously identified in analysis with the assistance of an external consultant are associated directly or indirectly with risks reported in the 'Risk Factors' section (Item 3.D) of the Form 20-F contained within our Annual Report. The Board does not consider that the Group has any material exposure to ESG risks other than those disclosed in the 'Risk Factors' section of the Form 20-F contained within the Annual Report.

PRINCIPLE 8.

REMUNERATE FAIRLY AND RESPONSIBLY

NOMINATION AND REMUNERATION COMMITTEE

As mentioned above in Principle 2, the Board has established a combined Nomination and Remuneration Committee. The Nomination and Remuneration Committee advises the Board on remuneration and incentive policies and practices generally and makes specific recommendations on remuneration packages and other terms of employment for executive Directors, other senior executives and non-executive Directors. Committee members receive regular briefings from an external remuneration expert on recent developments on remuneration and related matters. Details of the committee's charter, role and responsibilities, composition, structure, membership and attendance at meetings by members can be found under Principle 2 of this Statement.

NON-EXECUTIVE INDEPENDENT DIRECTOR REMUNERATION POLICY

Non-executive Independent Director remuneration is set out in the Remuneration Report. Non-executive Directors (i.e. for the purposes of this section, Directors who do not hold an executive position or have a consulting role with the Group) have been granted options following authorization from shareholders when they joined the Board. In addition, for the 2024 financial year and 2025 financial year, the non-executive Directors were granted options, which were approved by shareholders, for 50% of their directors' fees as a cash preservation strategy.

For the 2026 financial year, non-executive Directors reverted to receiving their directors' fees entirely in cash. All options granted to non-executive Directors are not subject to any performance or service hurdles or conditions. Further, non-executive Director remuneration does not include any performance-based remuneration or bonuses.

Further information on non-executive Directors' remuneration for the 2026 financial year, including principles used to determine remuneration, is set out in the Remuneration Report.

EXECUTIVE DIRECTOR AND SENIOR EXECUTIVES' REMUNERATION POLICY

Executive remuneration consists of fixed pay, performance-based remuneration and equity-based remuneration, and is closely aligned to the success of the Group. Further information on the executive Directors' and senior executives' remuneration for the 2026 financial year, including principles used to determine remuneration, is set out in the Remuneration Report.

SHARE TRADING POLICY

The Company has developed a share trading policy which governs the trading of the Company's shares by Directors, employees and consultants of the Company – who collectively are known as 'Mesoblast Personnel'. Mesoblast Personnel are not permitted to trade in the Company's securities during the period starting a week prior to the last business day of the month prior to the release of our quarterly financial results and ending one day after the release of those financial results. The Board may also impose additional blackout periods from time to time.

In addition, no person is able to trade in the Company's shares whilst in the possession of inside information, and nor are they able to influence any other person with regard to trading in the Company's shares.

The share trading policy prohibits Mesoblast Personnel from trading in the Company's derivatives. This prohibition is in place to prevent such personnel from limiting their economic exposure to risk arising out of an element of remuneration which has not vested, or which has vested but remains the subject of a disposal restriction.

A copy of the Company's share trading policy can be found at the Corporate Governance section of the Company's website, www.mesoblast.com.